BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Kanizaj TF, Kunac N. Helicobacter pylori: Future perspectives in therapy reflecting three decades of experience. World J Gastroenterol 2014; 20(3): 699-705 [PMID: 24574743 DOI: 10.3748/wjg.v20.i3.699] [Cited by in CrossRef: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 O'connor A, Furuta T, Gisbert JP, O'morain C. Review – Treatment of Helicobacter pylori infection 2020. Helicobacter 2020;25. [DOI: 10.1111/hel.12743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
2 Wang Y, Zhao R, Wang B, Zhao Q, Li Z, Zhu-ge L, Yin W, Xie Y. Sequential versus concomitant therapy for treatment of Helicobacter pylori infection: an updated systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:1-13. [DOI: 10.1007/s00228-017-2347-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
3 Jing ZW, Luo M, Jia YY, Li C, Zhou SY, Mei QB, Zhang BL. Anti-Helicobacterpylori effectiveness and targeted delivery performance of amoxicillin-UCCs-2/TPP nanoparticles based on ureido-modified chitosan derivative. Int J Biol Macromol. 2018;115:367-374. [PMID: 29660462 DOI: 10.1016/j.ijbiomac.2018.04.070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
4 Mahachai V, Vilaichone RK, Pittayanon R, Rojborwonwitaya J, Leelakusolvong S, Maneerattanaporn M, Chotivitayatarakorn P, Treeprasertsuk S, Kositchaiwat C, Pisespongsa P, Mairiang P, Rani A, Leow A, Mya SM, Lee YC, Vannarath S, Rasachak B, Chakravuth O, Aung MM, Ang TL, Sollano JD, Trong Quach D, Sansak I, Wiwattanachang O, Harnsomburana P, Syam AF, Yamaoka Y, Fock KM, Goh KL, Sugano K, Graham D. Helicobacter pylori management in ASEAN: The Bangkok consensus report. J Gastroenterol Hepatol. 2018;33:37-56. [PMID: 28762251 DOI: 10.1111/jgh.13911] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 12.8] [Reference Citation Analysis]
5 Almeida N, Donato MM, Romãozinho JM, Luxo C, Cardoso O, Cipriano MA, Marinho C, Fernandes A, Calhau C, Sofia C. Beyond Maastricht IV: are standard empiric triple therapies for Helicobacter pylori still useful in a South-European country? BMC Gastroenterol 2015;15:23. [PMID: 25886722 DOI: 10.1186/s12876-015-0245-y] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 1.1] [Reference Citation Analysis]
6 Abdel-Latif MM, Abouzied MM. Molecular Mechanisms of Natural Honey Against H. pylori Infection Via Suppression of NF-κB and AP-1 Activation in Gastric Epithelial Cells. Arch Med Res 2016;47:340-8. [PMID: 27751367 DOI: 10.1016/j.arcmed.2016.09.002] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
7 Hajaghamohammadi A, Safiabadi Tali SH, Samimi R, Oveisi S, Kazemifar AM. Low dose furazolidone for eradication of H- pylori instead of clarithromycin: a clinical trial. Glob J Health Sci 2014;7:235-9. [PMID: 25560342 DOI: 10.5539/gjhs.v7n1p235] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
8 Huang Y, Hang X, Jiang X, Zeng L, Jia J, Xie Y, Li F, Bi H. In Vitro and In Vivo Activities of Zinc Linolenate, a Selective Antibacterial Agent against Helicobacter pylori. Antimicrob Agents Chemother. 2019;63. [PMID: 30936098 DOI: 10.1128/aac.00004-19] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 3.3] [Reference Citation Analysis]
9 Reshetnyak VI, Burmistrov AI, Maev IV. Helicobacter pylori: Commensal, symbiont or pathogen? . World J Gastroenterol 2021; 27(7): 545-560 [PMID: 33642828 DOI: 10.3748/wjg.v27.i7.545] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
10 Gou QY, Shi RH, Yu RB. Levofloxacin containing triple therapy vs standard triple therapy for eradication of Helicobacter pylori: A Meta-analysis. Shijie Huaren Xiaohua Zazhi 2014; 22(33): 5207-5211 [DOI: 10.11569/wcjd.v22.i33.5207] [Reference Citation Analysis]
11 Rao J, Yang Y, Pan Bei H, Tang CY, Zhao X. Antibacterial nanosystems for cancer therapy. Biomater Sci 2020;8:6814-24. [PMID: 33078786 DOI: 10.1039/d0bm01537g] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
12 Jing Z, Jia Y, Wan N, Luo M, Huan M, Kang T, Zhou S, Zhang B. Design and evaluation of novel pH-sensitive ureido-conjugated chitosan/TPP nanoparticles targeted to Helicobacter pylori. Biomaterials 2016;84:276-85. [DOI: 10.1016/j.biomaterials.2016.01.045] [Cited by in Crossref: 47] [Cited by in F6Publishing: 47] [Article Influence: 7.8] [Reference Citation Analysis]
13 Frydman GH, Davis N, Beck PL, Fox JG. Helicobacter pylori Eradication in Patients with Immune Thrombocytopenic Purpura: A Review and the Role of Biogeography. Helicobacter 2015;20:239-51. [PMID: 25728540 DOI: 10.1111/hel.12200] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
14 Metanat HA, Valizadeh SM, Fakheri H, Maleki I, Taghvaei T, Hosseini V, Bari Z. Comparison Between 10- and 14-Day Hybrid Regimens for Helicobacter pylori Eradication: A Randomized Clinical Trial. Helicobacter. 2015;20:299-304. [PMID: 25752357 DOI: 10.1111/hel.12202] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 2.0] [Reference Citation Analysis]
15 Kwon YH, Jeon SW, Nam SY, Lee HS, Park JH. Efficacy of tailored therapy for Helicobacter pylori eradication based on clarithromycin resistance and survey of previous antibiotic exposure: A single-center prospective pilot study. Helicobacter. 2019;24:e12585. [PMID: 30969459 DOI: 10.1111/hel.12585] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
16 Igarashi H, Maeda S, Ohno K, Horigome A, Odamaki T, Tsujimoto H. Effect of oral administration of metronidazole or prednisolone on fecal microbiota in dogs. PLoS One 2014;9:e107909. [PMID: 25229475 DOI: 10.1371/journal.pone.0107909] [Cited by in Crossref: 59] [Cited by in F6Publishing: 55] [Article Influence: 7.4] [Reference Citation Analysis]
17 Rech TF, Mazzoleni LE, Mazzoleni F, Francesconi CFM, Sander GB, Michita RT, Nabinger DD, Milbradt TC, Torresini RJS, Simon D. Helicobacter pylori eradication: influence of interleukin-1beta -31 C/T polymorphism. Braz J Infect Dis 2018;22:311-6. [PMID: 30048609 DOI: 10.1016/j.bjid.2018.06.005] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
18 Arif M, Dong Q, Raja MA, Zeenat S, Chi Z, Liu C. Development of novel pH-sensitive thiolated chitosan/PMLA nanoparticles for amoxicillin delivery to treat Helicobacter pylori. Materials Science and Engineering: C 2018;83:17-24. [DOI: 10.1016/j.msec.2017.08.038] [Cited by in Crossref: 35] [Cited by in F6Publishing: 33] [Article Influence: 8.8] [Reference Citation Analysis]
19 Flint A, Stintzi A, Saraiva LM. Oxidative and nitrosative stress defences of Helicobacter and Campylobacter species that counteract mammalian immunity. FEMS Microbiol Rev 2016;40:938-60. [PMID: 28201757 DOI: 10.1093/femsre/fuw025] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 5.3] [Reference Citation Analysis]
20 Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC. CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for Helicobacter pylori eradication. World J Clin Cases 2018; 6(12): 514-520 [PMID: 30397607 DOI: 10.12998/wjcc.v6.i12.514] [Cited by in CrossRef: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
21 Orta de Velásquez MT, Yáñez Noguez I, Casasola Rodríguez B, Román Román PI. Effects of ozone and chlorine disinfection on VBNC Helicobacter pylori by molecular techniques and FESEM images. Environ Technol 2017;38:744-53. [PMID: 27432258 DOI: 10.1080/09593330.2016.1210680] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]